Catalent Inc (CTLT) Coverage Initiated by Analysts at Needham & Company LLC
Needham & Company LLC assumed coverage on shares of Catalent Inc (NASDAQ:CTLT) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.
A number of other analysts also recently commented on CTLT. BidaskClub raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Wells Fargo & Company restated an “outperform” rating and set a $39.00 target price (up previously from $30.00) on shares of Catalent in a research report on Thursday, August 31st. Jefferies Group LLC restated a “hold” rating and set a $38.00 target price (up previously from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Finally, J P Morgan Chase & Co restated a “buy” rating and set a $40.00 target price on shares of Catalent in a research report on Tuesday, August 29th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and a consensus price target of $36.22.
Catalent (NASDAQ:CTLT) remained flat at $40.79 on Tuesday. The stock had a trading volume of 552,425 shares. Catalent has a 52 week low of $21.83 and a 52 week high of $42.22. The company has a market capitalization of $5.11 billion and a PE ratio of 46.89. The company’s 50 day moving average is $36.26 and its 200-day moving average is $33.20.
Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to the consensus estimate of $547.48 million. Catalent had a net margin of 4.88% and a return on equity of 16.95%. The firm’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 earnings per share. Equities research analysts expect that Catalent will post $1.60 earnings per share for the current year.
In other Catalent news, SVP Christine Dolan sold 745 shares of Catalent stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Large investors have recently bought and sold shares of the company. Municipal Employees Retirement System of Michigan raised its position in shares of Catalent by 1.6% in the first quarter. Municipal Employees Retirement System of Michigan now owns 57,810 shares of the company’s stock valued at $1,637,000 after buying an additional 910 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Catalent in the second quarter valued at approximately $3,334,000. American International Group Inc. raised its position in shares of Catalent by 4.1% in the first quarter. American International Group Inc. now owns 306,375 shares of the company’s stock valued at $8,677,000 after buying an additional 12,021 shares during the last quarter. Eagle Asset Management Inc. raised its position in shares of Catalent by 4.3% in the first quarter. Eagle Asset Management Inc. now owns 291,451 shares of the company’s stock valued at $8,253,000 after buying an additional 12,063 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in shares of Catalent by 12.3% in the first quarter. Parametric Portfolio Associates LLC now owns 153,781 shares of the company’s stock valued at $4,355,000 after buying an additional 16,856 shares during the last quarter.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.